Mon, Apr 21, 2014, 8:25 AM EDT - U.S. Markets open in 1 hr 5 mins

Recent

% | $
Quotes you view appear here for quick access.

Hyperion Therapeutics, Inc. (HPTX) Message Board

vvvvvvrebel89130 980 posts  |  Last Activity: 12 hours ago Member since: Sep 15, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • vvvvvvrebel89130 vvvvvvrebel89130 Apr 1, 2014 10:38 AM Flag

    exact opposite; baxer and gsk both reported no statistical sig on o/s; no reason to expect we will either

    even if we report no stat sig on o/s, this is still a $10 stock on value alone with pos phase ii
    as i understand it, o/s is significant as the fda requires it for approval here; they don't in europe

    i'm lowballing it; o/s is a powerball ticket if we can pull it out
    still expect double digits here shortly; ecyt has moved up 14% after their secondary; we will get our turn

    long, way long

    Sentiment: Strong Buy

  • vvvvvvrebel89130 vvvvvvrebel89130 Apr 1, 2014 9:54 AM Flag

    were they even close on o/s?

    interesting they put the details out and oxgn didn't which supports that ours might be somewhat better

    i've been saying if o/s was a total bust, they would have said so like gsk just did; also, baxter said no change in o/s yet oxgn was strangely silent on o/s

    we got a 1% chance i figure of statistical sig in o/s

    Sentiment: Strong Buy

  • vvvvvvrebel89130 vvvvvvrebel89130 Apr 1, 2014 9:26 AM Flag

    big is the xpert here so read his posts
    we have positive phase ii results; met our primary end point; still waiting on o/s but i doubt very seriously we will show any better results than gsk

    the fact that gsk is withdrawing makes us much more attractive and frankly more valuable

    as far as i can tell, ecyt and us are the only ovarian cancer stocks left moving forward

    heres something for you; just noticed ecyt did an offering at 21, few days ago; stock is up to 24; 14% gain in days

    someday market will discover oxgn

    good luck

    The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less than 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone.

    Sentiment: Strong Buy

  • well, looks like we won't be seeing any o/s benefit; no one has reported any o/s benefit, no reason to expect oxgn will either; calling it the way i see it

    still, this clears the the way for oxgn

    only competitor is ecyt

    LONDON--Drug group GlaxoSmithKline PLC (GSK) said Monday it has withdrawn a European Union application related to its ovarian cancer treatment Votrient after analyzing data from a phase III study. "We believe that, in spite of the improvement in progression free survival observed in our Phase III study, the totality of the evidence including these more mature OS [overall survival] data, do not support an overall positive benefit-risk for Votrient in this indication," said Rafael Amado, head of oncology research and development at Glaxo. "While we are disappointed by these results, we will progress additional analyses which may add to the body of scientific evidence in this disease setting." Shares at 1215 GMT, down 13 pence, or 0.77%, at 1,606 pence valuing the company at 78 billion pounds ($129.8 million).

    Sentiment: Strong Buy

  • Reply to

    Same thin happened to SRPT

    by bntj1o Mar 31, 2014 11:48 AM
    vvvvvvrebel89130 vvvvvvrebel89130 Mar 31, 2014 3:08 PM Flag

    bs; srpt spiked from 14 to 45 on great news and was gang raped by hedgys down to the mid 20's

    steller results

    met all endpoints unlike some unnamed company

    Sentiment: Hold

  • Reply to

    aggie/missing post/k hill

    by vvvvvvrebel89130 Mar 31, 2014 12:45 PM
    vvvvvvrebel89130 vvvvvvrebel89130 Mar 31, 2014 1:59 PM Flag

    cool; have no clue who our qb is, we might take him; can't remember and don't really care if wittek the usc qb transfer picks us; last i heard he was checking out hawaii; hill was red shirted last year; he transfers, he sits out another year; heck he might not ever play; his dad calvin is in charge of the cowboys and has kept a pretty close reign on them; actions have consequences; joekel looked pretty darn good against rice; still looks like you got 3 in the top 12 or so in the draft; very impressive

    gl

    Sentiment: Strong Buy

  • vvvvvvrebel89130 vvvvvvrebel89130 Mar 31, 2014 12:53 PM Flag

    pretty sure he said another shrieking alpha article was on the way

    could be a real nice run into accr with 3 presentations, next sun-tues

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 Mar 31, 2014 12:45 PM Flag

    yahoo wacked your post earlier today?
    kenny hill; thats just embarrassing; makes me wonder about scl

    gl

    Sentiment: Strong Buy

  • The trading desks of four different major financial institutions posted gains every single day during the first quarter of 2010. The tradings desks of JP Morgan (JPM), Bank of America (BAC), Citigroup (C) and Goldman Sachs (GS) combined posted 244 winning trading days against zero losses.

    Were the playing field truly level the odds of a firm making profits or losses on any given day would be roughly 50%. The chances of going 61-0 on such a trading field of dreams would be 2.31 quintillion to 1. The chances of Goldman, Citi, Bank of America and Goldman independently posting 61 winning days in a row are roughly the same as four best friends in completely different sides of the world each winning Powerball, getting attacked by a shark and dying from Fugu sushi poisoning.

    Less than two months after the end of this collective perfect quarter the market experienced a “flash crash” that drove the Dow down more than 1,000 points in minutes.

    Sentiment: Strong Buy

  • Reply to

    One more thought, 235 million in nol's

    by stocktraderj Mar 30, 2014 9:24 AM
    vvvvvvrebel89130 vvvvvvrebel89130 Mar 30, 2014 8:32 PM Flag

    where are you getting your cash numbers from? oxgn reported 25mm; root said they told him 30mm and i don't buy that for a second

    as for why the stock is trading like this; it's retail held; you'll see the diff when we break $5 and the tutes swallow up the float

    right now you have retail longs and shorts jerking each other around for pennies with a 15mm float

    what do you think happens when fidelitiy and vanguard come in above $5 and the float shrinks by about 5mm down to 10mm

    plug ran from 5 to 11 in days after breaking $5

    we break $5, we see double digits

    next 1.50 in the stock gets us another 5

    Sentiment: Strong Buy

  • Reply to

    big sound familiar?

    by vvvvvvrebel89130 Mar 29, 2014 5:48 PM
    vvvvvvrebel89130 vvvvvvrebel89130 Mar 30, 2014 9:45 AM Flag

    non-toxic, increased pfs and no chemo

    nothing wrong except it's valuation

    really looking forward to the abstracts; one is for prostate cancer, not sure what the other 2 are about but it shows advancing the platform which makes oxgn more valuable and attractive

    Sentiment: Strong Buy

  • Reply to

    One more thought, 235 million in nol's

    by stocktraderj Mar 30, 2014 9:24 AM
    vvvvvvrebel89130 vvvvvvrebel89130 Mar 30, 2014 9:39 AM Flag

    in my opinion, the stock should be valued at 200mm cap or 10/shr based on the results, pipeline, and cash in the bank right now;

    undervalued by 3x

    also, i'm starting to suspect that's why there is no deal; hopefully, ceo and bod agree that any buyout in the 10 range is basically getting the company for free

    longer we wait on a deal the better as far as i'm concerned

    no deal talk until we're in double digits and i suspect oxgn mgmt feels the same way

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 Mar 29, 2014 5:48 PM Flag

    i suspect ecyt won't present at aacr for ovarian
    i read multiple articles on ecyt on their yahoo news page; its scary how similar oxgn and ecyt are except for the valuation

    these 3 abstracts being presented at aacr are important as they show continued progress in the rest of the pipeline which was mentioned multiple times in the ecyt articles

    gl

    In NSCLC, Endocyte tested the drug alone and in combination with docetaxel, with a group receiving docetaxel alone for comparison. The trial met the predefined threshold for statistical significance of achieving a p-value of less than 0.10 for its progression-free survival (PFS) endpoint. However, the company did not break down the numbers for survival or report on secondary endpoints (including overall survival), saying that it would present those results at an upcoming medical conference.

    Sentiment: Strong Buy

  • Reply to

    76k at 3.55

    by vvvvvvrebel89130 Mar 28, 2014 3:57 PM
    vvvvvvrebel89130 vvvvvvrebel89130 Mar 28, 2014 4:59 PM Flag

    no, they were teasing; flashed off right at close but shows that someone is out there looking to buy big and also shows that no one was willing to lower their cell price by a penny

    could be the start of a really nice run

    next week leading into aacr, and then i think we present abstracts on sunday-mon-tues

    gl

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 Mar 28, 2014 3:57 PM Flag

    knock knock, someone wants in

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 Mar 28, 2014 3:51 PM Flag

    pretty big chunk

    Sentiment: Strong Buy

  • vvvvvvrebel89130 vvvvvvrebel89130 Mar 28, 2014 9:49 AM Flag

    very well said; so why did the fda turn down baxter here due to no increase in o/s?

    the huge advantage oxgn has is that it eliminates the horror of chemo; is that enuff to sway the fda even if o/s doesn't increase?

    Sentiment: Strong Buy

  • Reply to

    AACR & ASCO Deadlines

    by manofeconomics Mar 27, 2014 7:20 PM
    vvvvvvrebel89130 vvvvvvrebel89130 Mar 28, 2014 8:57 AM Flag

    man, so the lead researcher told oxgn the results on march 11; can oxgn share the full results with potential partners even if the results are embargoed?

    Sentiment: Strong Buy

  • vvvvvvrebel89130 vvvvvvrebel89130 Mar 28, 2014 8:28 AM Flag

    i thought adam f's only comment on oxgn was relatively positve by his standards which i find very telling

    his comments were "surprising"
    i still think adam f has gone silent because his hedgy cronies are building a big position down here

    when the time comes, adam f will come out with some headline like "oxgn new cancer cure?" or something like that and away we go

    i don't get people downgrading the importance of o/s; is it a primary end point? no. is it important? hell yes
    if we get statistically significant o/s, this is a triple digit stock; if not, we are bought/partnered in the nice double digit range

    did you and big consider that any deal might be on hold until the full results are released and their impact is reflected in the stock price?

    i agree with the earlier poster; it's unilikely you will see a $20 offer for a stock trading in the 3's

    however, once the results come out and the stock spikes to $10 or more, then a buyout in the 20's or more is much more likely

    per manofeconomics, he said the ceo said the results are embargoed, most likely until asco in june
    so, does oxgn know the results? were they double blinded?

    oxgn might not know the results and it appears like they won't be able to share them with any suitors as they're embargoed

    i suspect any deal doesn't happen until after the results are released

    i'm cool with that too
    looking forward to the pre-clinical abstracts as that will show progress in the rest of the pipeline

    Sentiment: Strong Buy

  • vvvvvvrebel89130 vvvvvvrebel89130 Mar 27, 2014 8:46 PM Flag

    let's flip it; what if oxgn is willing to wait for the flop? is it double blinder? any anecdotal evidence that o/s might show statistical significance?

    also, you're 200mm buyout is 10, which is where i think the company belongs right now;

    we will get good preclinical news from the abstracts at aacr which will add heat to the fire; more positive news in more indications showing a wide range of success in different indications using the platform; i noted one of the abstracts is for prostate, couldn't figure out the other 2

    gl

    Sentiment: Strong Buy

HPTX
24.71-0.26(-1.04%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.